Richard F. Kefford
Broad Institute · 601 works · 94,082 citations · h-index 125
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Genome-wide association study identifies novel breast cancer susceptibility loci
- Genomic Classification of Cutaneous Melanoma
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- The repertoire of mutational signatures in human cancer
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- Pan-cancer analysis of whole genomes
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab